Saturday, 5 September 2026European Markets

SPORTING Stock 9.83% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with SPORTING (SCP.LS) rising 9.83% to €0.95 on Friday, following the last session's upward trend. PSI slid 1.13% to €6,737.11, after three successive sessions in a row of losses, on what was an all-around bearish trend trading session today.

SPORTING's last close was €0.87, 8.95% under its 52-week high of €0.95.

About SPORTING

Sporting Clube de Portugal - Futebol, SAD operates sports clubs in Portugal. The company also engages in the sale of tickets for games; advertising and sponsorships activities; and provision of television rights. Sporting Clube de Portugal - Futebol, SAD was founded in 1907 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, SPORTING has a trailing twelve months EPS of €0.18.

PE Ratio

SPORTING has a trailing twelve months price to earnings ratio of 5.28. Meaning, the purchaser of the share is investing €5.28 for every euro of annual earnings.

Volume

Today's last reported volume for SPORTING is 98 which is 93.76% below its average volume of 1571.

Yearly Top and Bottom Value

SPORTING's stock is valued at €0.95 at 22:30 EST, way under its 52-week low of €0.65.

More news about SPORTING (SCP.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com